Register for our free email digests:
Vanda Pharmaceuticals Inc.
www.vandapharma.com
Latest From Vanda Pharmaceuticals Inc.
US PTO's Patent Eligibility Guidance Draws Industry Plaudits, Request For More Specifics
BIO, PhRMA, Novartis, Amgen, and Genentech suggest revisions to guidance on hot-button issue of subject matter patent eligiblity; patent owners group says 'best approach' is to enact legislation to restore patent eligibility law.
Vanda Puts Dog Studies In Spotlight In Suit Challenging FDA Clinical Hold
Vanda seeks court order requiring US FDA to lift partial clinical hold on its gastroparesis treatment tradipitant; calls on drug makers to oppose agency's animal research policy, saying it requires unjustified killing of dogs.
Federal Circuit Tosses Diagnostic Patent, Spurring Biopharma Calls For Congressional Action
A divided panel finds Athena Diagnostics' patent on method to diagnose myasthenia gravis is invalid; in dissent, Judge Newman cites industry concerns that the decision will deter development of new diagnostic methods.
Hazards Ahead For New Drugs At US FDA Amid Safety Concerns, Shutdown Disruption
The pipeline for new drug candidates remains healthy as 2019 begins, with almost 40 novel agents already under FDA review. But the chances of another record-breaking year are threatened by a confluence of safety issues that are putting risk management back in the spotlight – and by the widening ripple effects of the recent US government shutdown.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Therapeutic Areas
- Dermatology
- Neurology, Nervous System
- Respiratory, Pulmonary
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Vanda Pharmaceuticals Inc.
- Senior Management
-
Mihael H Polymeropoulos, MD, Pres. & CEO
James Kelly, EVP, CFO & Treasurer
Gunther Birznieks, SVP, Bus. Dev.
Deepak Phadke, PhD, VP, Manufacturing
Gian Piero Reverberi, SVP, Chief Commercial Officer - Contact Info
-
Vanda Pharmaceuticals Inc.
Phone: (202) 734-3400
2200 Pennsylvania Ave. NW
Ste. 300E
Washington, DC 20037
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice